GlassScriptPhysician profile
Leif A Lohrbauer
NPI 1427021591
$1,101.17
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $234 · 2021: $260 · 2022: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $212.63 | 2019-2021 | |
| Abbott Laboratories | $146.76 | 2021 | |
| Esperion Therapeutics, INC. | $124.38 | 2020 | |
| Acelrx Pharmaceuticals, INC. | $109.19 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $77.43 | 2019 | |
| Gilead Sciences, INC. | $64.21 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.50 | 2019 | |
| Astellas Pharma US INC | $34.64 | 2019 | |
| Amgen INC. | $28.72 | 2019 | |
| Pfizer INC. | $24.54 | 2019 | |
| Braemar Manufacturing, LLC | $20.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.52 | 2019 | |
| Boston Scientific Corporation | $11.97 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leif Lohrbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.